TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 79.4%

Neg 0% Neu 0% Pos 79.4%

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $117 to $125.